Last reviewed · How we verify
Xylocaine 10% pump spray
At a glance
| Generic name | Xylocaine 10% pump spray |
|---|---|
| Also known as | Lidocaine 10% pump spray |
| Sponsor | Krankenhaus Barmherzige Schwestern Linz |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of 10% Lidocaine on Relieving Pain Caused by Intravenous Intubation (PHASE3)
- Role of Airway Topicalization in Awake Fiberoptic Intubation (PHASE3)
- Use of Chitosan Powder in Loop Electrosurgical Excision Procedure (PHASE4)
- VENLID: The Application of a 10%-Lidocaine Spray Prior to the Insertion of a Peripheral Intra-venous Catheter in Female Adults (PHASE4)
- Anesthesia on Postoperative Pain After Loop Electrosurgical Excision Procedure (NA)
- Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat (PHASE3)
- Pain Relief During Intravenous Cannulation in Pediatric Patients (PHASE4)
- Evaluation of the Effect of 10% Lidocaine Spray Undergoing Coronary Artery Bypass Graft Operation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xylocaine 10% pump spray CI brief — competitive landscape report
- Xylocaine 10% pump spray updates RSS · CI watch RSS
- Krankenhaus Barmherzige Schwestern Linz portfolio CI